Epiomic Epidemiology Series: Hypertrophic Cardiomyopathy Forecast in 26 Major Markets 2018–2028

July 2018 | 112 pages | ID: E7A927DB5B5EN
Black Swan Analysis limited

Abstracts

Black Swan Analysis Epiomic Epidemiology Series Forecast Report on Hypertrophic Cardiomyopathy in 26 Major Markets

Hypertrophic cardiomyopathy (HCM) is a disease that contains an autosomal dominant inheritance pattern and is a moderately common “transmitted” genetic disease. The disease, characterised by hypertrophy in the left ventricle, cannot be explained by the presence of other clinical symptoms, such as hypertension.

This report provides the current prevalent population for HCM across 26 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Belgium, Norway, Sweden, Denmark, Austria, Switzerland, Ireland, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the types, occlusion locations and the prevalence of associated disorders of HCM. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of HCM have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for HCM include:

• Chronic heart failure
• Angina pectoris
• Atrial fibrillation
• Tachycardia

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Ability to quantify patient populations in global HCM market to target the development of future products, pricing strategies and launch plans.
• Further insight into the prevalence of the subdivided types of HCM and identification of patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Better understanding on the impact of specific co-morbid conditions on the prevalent population of HCM patients.
• Identification of HCM patient sub-populations that require treatment.
• Better understanding of the specific markets that have the largest number of HCM patients.

Contents

INTRODUCTION

CAUSE OF THE DISEASE

RISK FACTORS & PREVENTION

DIAGNOSIS OF THE DISEASE

VARIATION BY GEOGRAPHY/ETHNICITY

DISEASE PROGNOSIS & CLINICAL COURSE

KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE

METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS

TOP-LINE PREVALENCE FOR HYPERTROPHIC CARDIOMYOPATHY

FEATURES OF HYPERTROPHIC CARDIOMYOPATHY PATIENTS

GENETIC BACKGROUND

PARAMETERS AND SYMPTOMS

COMORBIDITIES OF HYPERTROPHIC CARDIOMYOPATHY PATIENTS

ABBREVIATIONS USED IN THE REPORT

OTHER BLACK SWAN SERVICES & SOLUTIONS

REPORTS & PUBLICATIONS

ONLINE EPIDEMIOLOGY DATABASES

ONLINE PHARMACEUTICAL PRICING DATABASE

REFERENCES

APPENDIX

List Of Tables

LIST OF TABLES AND FIGURES

Table 1. Prevalence of HCM, total (000s)
Table 2. Prevalence of HCM, males (000s)
Table 3. Prevalence of HCM, females (000s)
Table 4. Patients with HCM by genetic origin, total (000s)
Table 5. Patients with familial HCM by gene mutation, total (000s)
Table 6. Patients with sporadic HCM by gene mutation, total (000s)
Table 7. Familial HCM patients with MYBPC3 mutation by prognosis, total (000s)
Table 8. Familial HCM patients with MYH7 mutation by prognosis, total (000s)
Table 9. Familial HCM patients with TNNT2 mutation by prognosis, total (000s)
Table 10. Familial HCM patients with TNNI3 mutation by prognosis, total (000s)
Table 11. Familial HCM patients with MYL2 mutation by prognosis, total (000s)
Table 12. Patients with HCM by NYHA class, total (000s)
Table 13. Patients with HCM by maximum LV thickness (mm), total (000s)
Table 14. Patients with HCM by presence of symptoms, total (000s)
Table 15. Symptomatic HCM patients with dyspnoea, total (000s)
Table 16. Symptomatic HCM patients with dyspnoea by NYHA class, total (000s)
Table 17. Symptomatic HCM patients with clinical heart failure, total (000s)
Table 18. Symptomatic HCM patients with angina pectoris, total (000s)
Table 19. Symptomatic HCM patients with syncope, total (000s)
Table 20. Symptomatic HCM patients with near syncope, total (000s)
Table 21. Symptomatic HCM patients with paroxysmal supraventricular tachycardia, total (000s)
Table 22. Incidence of HCM-related deaths, total (000s)
Table 23. Incidence of HCM-related deaths by cause, total (000s)
Table 24. HCM patients with atrial fibrillation, total (000s)
Table 25. HCM patients with atrial fibrillation by type, total (000s)
Table 26. HCM patients with arterial hypertension, total (000s)
Table 27. HCM patients with outflow obstruction, total (000s)
Table 28. HCM patients with outflow obstruction by LVOT (mm Hg), total (000s)
Table 29. Abbreviations and acronyms used in the report
Table 30. USA prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
Table 31. USA prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
Table 32. Canada prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
Table 33. Canada prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
Table 34. France prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
Table 35. France prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
Table 36. Germany prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
Table 37. Germany prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
Table 38. Italy prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
Table 39. Italy prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
Table 40. Spain prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
Table 41. Spain prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
Table 42. UK prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
Table 43. UK prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
Table 44. Poland prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
Table 45. Poland prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
Table 46. Netherlands prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
Table 47. Netherlands prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
Table 48. Belgium prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
Table 49. Belgium prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
Table 50. Norway prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
Table 51. Norway prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
Table 52. Sweden prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
Table 53. Sweden prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
Table 54. Denmark prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
Table 55. Denmark prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
Table 56. Austria prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
Table 57. Austria prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
Table 58. Switzerland prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
Table 59. Switzerland prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
Table 60. Ireland prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
Table 61. Ireland prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
Table 62. Russia prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
Table 63. Russia prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
Table 64. Turkey prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
Table 65. Turkey prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
Table 66. Japan prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
Table 67. Japan prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
Table 68. China prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
Table 69. China prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
Table 70. South Korea prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
Table 71. South Korea prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
Table 72. India prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
Table 73. India prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
Table 74. Australia prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
Table 75. Australia prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
Table 76. Brazil prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
Table 77. Brazil prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
Table 78. Mexico prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
Table 79. Mexico prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)
Table 80. Argentina prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, males (000s)
Table 81. Argentina prevalence of hypertrophic cardiomyopathy by 5-yr age cohort, females (000s)